First AD

Second AD

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Inside the Clinic: Updates in Diagnosis, Treatment, and Management of Chronic Graft-Versus-Host Disease 

Insights

Expert perspectives on optimal treatment strategies for patients who develop steroid-refractory chronic graft-versus-host disease.

Identifying and Managing Steroid-Refractory Chronic GVHD

Background on Graft-vs-Host Disease: Risk Factors and Prevention

Acute vs Chronic GVHD: Identification and Stratification

Frontline Treatment Options for Chronic GVHD

Defining Steroid-Refractory and Steroid-Dependent GVHD

Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease

Mechanism of Action of Ruxolitinib

REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD

Chronic GVHD: Real-World Use of Ruxolitinib

Selecting Second-Line Therapy for Chronic GVHD

Chronic GVHD: Novel Treatment Approaches With Approved Agents

Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials

HSCT Approaches to Retain GVL While Preventing GVHD

Emerging Treatment Strategies for Chronic GVHD